{
    "clinical_study": {
        "@rank": "109355", 
        "acronym": "Hydrus III", 
        "arm_group": [
            {
                "arm_group_label": "Hydrus Microstent", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized to the Hydrus Microstent"
            }, 
            {
                "arm_group_label": "iStent Trabecular Micro Bypass", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients randomized to the iStent Trabecular Micro Bypass"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial compares two implantable devices intended to lower the pressure inside\n      the eye of glaucoma patients.  One of the two devices will be implanted immediately\n      following cataract surgery and the placement of a posterior chamber intra-ocular lens."
        }, 
        "brief_title": "Compare the Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Having Cataract Surgery (Hydrus III)", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Open Angle Glaucoma", 
            "Pseudoexfoliative Glaucoma", 
            "Pigmentary Dispersion Glaucoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Cataract"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, multicenter, single-masked, randomized clinical trial comparing\n      Cataract Extraction (CE) + Hydrus Microstent to CE surgery + iStent implant for the\n      reduction of intraocular pressure in patients with a positive diagnosis of primary open\n      angle glaucoma, pseudoexfoliative glaucoma, or pigmentary dispersion glaucoma with an\n      operable cataract.  Eligible patients will be scheduled for cataract surgery.  At the\n      conclusion of successful cataract surgery and the placement of a posterior-chamber IOL,\n      qualified subjects will be randomized to receive either the Hydrus Microstent or the iStent\n      implant.  Post-operative follow-up visits will be conducted at regular intervals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A diagnosis of primary open angle glaucoma (POAG), Pseudoexfoliative (PXG) glaucoma,\n             or Pigmentary dispersion glaucoma (PDG)\n\n          -  An operable age-related cataract with BCVA of 20/40 or worse, eligible for\n             phacoemulsification.\n\n        Exclusion Criteria:\n\n          -  Forms of primary or secondary glaucoma not listed above\n\n          -  Prior glaucoma surgery in the study eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024464", 
            "org_study_id": "CP-10-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hydrus Microstent", 
                "description": "Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.", 
                "intervention_name": "Hydrus Microstent", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "iStent Trabecular Micro Bypass", 
                "description": "Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.", 
                "intervention_name": "iStent Trabecular Micro Bypass", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Primary open angle glaucoma", 
            "POAG", 
            "Pseudoexfoliative glaucoma", 
            "PXG", 
            "Pigmentary dispersion glaucoma", 
            "PDG", 
            "Hydrus"
        ], 
        "lastchanged_date": "December 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Irvine", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92618"
                }, 
                "name": "Contact Brett Trauthen at Ivantis"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery", 
        "other_outcome": [
            {
                "description": "The proportion of eyes with IOP greater than 5 and less than or equal to 19 mmHg at 12  months after surgery.", 
                "measure": "Proportion of eyes with IOP greater than 5 and less than or equal to 19 mmHg.", 
                "safety_issue": "No", 
                "time_frame": "Month 12"
            }, 
            {
                "description": "Safety outcomes include loss of lines of BCVA, results of slit lamp and fundus examination, and the incidence of complications and adverse events.", 
                "measure": "Loss of best-corrected visual acuity (BCVA)", 
                "safety_issue": "Yes", 
                "time_frame": "Month 12"
            }
        ], 
        "overall_contact": {
            "email": "btrauthen@ivantisinc.com", 
            "last_name": "Brett Trauthen", 
            "phone": "949/333-1315"
        }, 
        "overall_contact_backup": {
            "email": "prhee@ivantisinc.com", 
            "last_name": "Paul Rhee, OD", 
            "phone": "949/333-1316"
        }, 
        "overall_official": {
            "affiliation": "Mississauga, ON, Canada", 
            "last_name": "Iqbal K. Ahmed, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Italy: Ministry of Health", 
                "Spain: Spanish Agency of Medicines", 
                "Poland: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary effectiveness endpoint for this study is IOP at 12 months following surgery.", 
            "measure": "Intraocular pressure at Month 12", 
            "safety_issue": "No", 
            "time_frame": "Twelve months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024464"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The proportion of patients requiring supplemental medication for pressure control.", 
            "measure": "Proportion of patients requiring supplemental medication.", 
            "safety_issue": "No", 
            "time_frame": "Month 12"
        }, 
        "source": "Ivantis, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ivantis, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}